SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI‐TUMOR ACTIVITY. (17th June 2021) - Hutchings, M